Osteoporosis and Low Bone Mass Affect 54 Million U.S. Adults Over 50
A landmark NHANES-based study estimates 10.2 million Americans have osteoporosis and another 43.4 million have low bone mass — more than half of all adults over 50.
Read the original article at Journal of Bone and Mineral ResearchKairos™'s Take
Kairos™'s perspective on this story
A study published in the Journal of Bone and Mineral Research used nationally representative NHANES data to estimate that 10.2 million adults aged 50 and older had osteoporosis at the femoral neck or lumbar spine, while another 43.4 million had low bone mass (osteopenia) at either site. Combined, that is 53.6 million people — roughly 54% of the entire U.S. population in that age group. The data make it clear that compromised bone health is not an edge case. It is the norm for aging Americans.
The study also highlighted a stark gender disparity: 15.4% of women over 50 had osteoporosis compared to 4.3% of men, and 51.4% of women had low bone mass versus 35.2% of men. These numbers underline a critical window — the years surrounding menopause — when hormonal shifts accelerate bone loss and early detection becomes most valuable.
Why This Matters for Midlife Health
The sheer scale of the problem reframes how we should think about bone health. With more than half of adults over 50 carrying some degree of bone deficit, the question shifts from "am I at risk?" to "how much risk am I carrying, and do I know about it?" Most of these 53.6 million people have no symptoms. Osteoporosis does not announce itself until a fracture happens, which is why population-level data like this reinforces the case for proactive screening — particularly during and after the menopausal transition when estrogen withdrawal drives the fastest phase of bone loss.
The Tracking Connection
Prevalence studies give us the macro picture. What they cannot do is tell any individual where they stand. That is where longitudinal tracking becomes essential. Platforms like Kairos™ let users log DXA results over time, monitor hormonal symptoms that correlate with bone loss, and bring organized data to their provider visits. When you can show a clinician a timeline — symptoms, lab values, scan results — the conversation shifts from reactive to strategic. Given that more than half the population over 50 is affected, the question is not whether tracking matters, but how early you start.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
SWAN Study: Bone Loss Accelerates Sharply During the Menopause Transition
The landmark SWAN longitudinal study showed that bone mineral density remains stable in early perimenopause but declines sharply in late perimenopause — about 2% per year — continuing into early postmenopause.
The FREEDOM Trial: Denosumab Reduces Vertebral Fractures by 68% in Postmenopausal Women
The landmark FREEDOM trial published in NEJM showed that denosumab, a monoclonal antibody, significantly reduced vertebral, hip, and nonvertebral fractures in women with osteoporosis over 3 years.
The Treatment Gap in Osteoporosis: Fewer Than 20% of High-Risk Patients Receive Care
A comprehensive review documents the growing osteoporosis treatment gap — with diagnosis rates below 20% and post-fracture treatment rates declining despite effective therapies being available.